• LAST PRICE
    6.4300
  • TODAY'S CHANGE (%)
    Trending Up0.4100 (6.8106%)
  • Bid / Lots
    6.3100/ 4
  • Ask / Lots
    7.0000/ 15
  • Open / Previous Close
    6.1100 / 6.0200
  • Day Range
    Low 5.9000
    High 6.4400
  • 52 Week Range
    Low 5.6700
    High 40.9800
  • Volume
    102,559
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 6.02
TimeVolumeGNLX
09:32 ET11246.07
09:34 ET1005.9
09:38 ET59915.9001
09:39 ET6506.2212
10:26 ET2006.055
11:13 ET4256.1892
11:54 ET1006.11
12:21 ET2006.15
12:34 ET2006.1005
12:52 ET1006.15
12:54 ET2546.192
01:08 ET30416.155
01:35 ET1006.06
01:39 ET1006.0601
01:57 ET2006.0975
02:15 ET2006.155
02:20 ET27566.2099
02:22 ET3156.1623
02:26 ET10006.2063
02:27 ET53846.225
02:36 ET2006.33
02:38 ET3006.3
03:02 ET1006.31
03:03 ET7006.31
03:21 ET6016.3396
03:45 ET2006.21
03:54 ET5006.22
03:56 ET13956.37
03:57 ET2006.38
03:59 ET313726.43
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGNLX
Genelux Corp
171.8M
-5.9x
---
United StatesMOLN
Molecular Partners AG
147.9M
-2.0x
---
United StatesPRQR
ProQR Therapeutics NV
186.3M
-6.1x
---
United StatesSYRS
Syros Pharmaceuticals Inc
137.3M
-0.9x
---
United StatesSGMT
Sagimet Biosciences Inc
173.0M
-4.1x
---
United StatesCOYA
Coya Therapeutics Inc
144.3M
-12.1x
---
As of 2024-03-29

Company Information

Genelux Corporation is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of oncolytic viral immunotherapies for patients suffering from solid tumor types. Its advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. The Company is focused on Phase II clinical trial of Olvi-Vec in platinum resistant/refractory ovarian cancer (PRROC). Its Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT) Immunotherapy is an indication-agnostic personalized anti-cancer therapy designed to safely maximize the number and effect of cancer neoantigen-specific effector T cells within cancer tissues. Its animal health product candidate, V-VET1, is a genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus that is a naturally attenuated isolate.

Contact Information

Headquarters
2625 Townsgate Road, Suite 230WESTLAKE VILLAGE, CA, United States 91361
Phone
805-267-9889
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Thomas Zindrick
Chief Financial Officer
Lourie Zak
Vice President of Pharmaceutical Development, General Manager of Manufacturing
Joseph Cappello
Vice President - Clinical Trial Operations
Tony Yu
General Counsel, Corporate Secretary
Sean Ryder

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$171.8M
Revenue (TTM)
$238.0K
Shares Outstanding
26.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.09
Book Value
$-1.46
P/E Ratio
-5.9x
Price/Sales (TTM)
721.8
Price/Cash Flow (TTM)
---
Operating Margin
-8,680.67%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.